Nexalin Technology, Inc. (NASDAQ: NXL)

Nexalin Technology, Inc. designs and develops innovative neurostimulation products to combat the global mental health epidemic. The company's primary focus is on creating easy-to-administer medical devices that utilize bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy. Nexalin's original Generation 1 (Gen-1) devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment and are classified by the U.S. Food and Drug Administration (FDA) as a Class II device. The company is also developing advanced Generation 2 (Gen-2) and Generation 3 (Gen-3) devices, branded as SYNC and HALO respectively, which utilize a new 15 milliamp waveform and are designed to penetrate deeper into the brain for enhanced patient response.

Nexalin generates revenue through the sale and leasing of its neurostimulation devices, as well as through monthly licensing fees and payments for the sale of electrodes and patient cables. The company's primary products include the Gen-1, Gen-2 SYNC, and Gen-3 HALO devices, which cater to the mental health industry. Nexalin's customer base includes medical professionals and patients seeking non-pharmacological treatments for mental health disorders. The company also derives revenue from servicing previously sold or leased devices, including warranty coverage, electrode sales, and patient cable replacement.

• Gen-1 Devices: Nexalin's original Gen-1 devices are CES devices that emit a waveform at 4 milliamps. These devices are designed to treat anxiety, insomnia, and depression and are classified by the FDA as Class II devices. The Gen-1 devices cater to the mental health industry, providing a non-invasive treatment option for patients.

• Gen-2 SYNC Devices: The Gen-2 SYNC devices represent an advancement in Nexalin's technology, utilizing a new 15 milliamp waveform. These devices are designed to penetrate deeper into the brain, stimulating deep brain structures associated with mental illness. The Gen-2 SYNC devices are intended for clinical use and are part of Nexalin's strategy to disrupt the traditional mental health treatment model.

• Gen-3 HALO Devices: The Gen-3 HALO devices are designed to be prescribed by licensed medical professionals in a virtual clinic setting. These devices utilize the new 15 milliamp waveform and are intended to provide a cost-effective and efficient treatment model for day-to-day mental health challenges. The HALO devices are part of Nexalin's mission to remove the stigma associated with mental health treatment and provide clinically proven technology that is easily accessible in the privacy of the patient's home.

Nexalin Technology, Inc. operates in the competitive mental health industry, where it faces competition from other companies developing neurostimulation devices and alternative treatments for mental health disorders. The company's competitive advantages include its proprietary 15 milliamp waveform technology, which is designed to penetrate deeper into the brain and stimulate deep brain structures associated with mental illness. Nexalin's advanced waveform technology is undetectable to the human body, allowing for increased power without incurring any patient discomfort, risk, or adverse side effects. The company's focus on developing a modern headset monitored with an IT management platform positions it to disrupt the traditional mental health treatment model and provide a non-invasive, cost-effective alternative to pharmaceuticals and psychotherapy.

Nexalin Technology, Inc. serves a broad customer base, including medical professionals and patients seeking non-pharmacological treatments for mental health disorders. The company's devices are designed to cater to the growing demand for safe, effective, and drug-free alternatives to traditional mental health treatments. Nexalin's focus on developing a virtual clinic model and a proprietary IT management platform aims to enhance the patient experience and provide a comprehensive solution for mental health treatment. The company's commitment to innovation and its proprietary technology position it as a key player in the mental health industry, with the potential to make a significant impact on the treatment of mental health disorders.